A Rundown of Dravet Syndrome Drugs In The Pipeline

2 / 8
GW Pharmaceuticals
GW Pharmaceuticals

GW Pharmaceuticals plc’s (GWPH) investigational drug for Dravet syndrome Epidiolex is under priority review by the FDA.

Epidiolex, an oral solution of pure plant-derived cannabidiol, or CBD, is designated an orphan drug for Dravet syndrome by the FDA and the European Medicines Agency.

The FDA's decision on Epidiolex in the treatment of Dravet syndrome is expected on June 27, 2018.

GWPH closed Thursday’s (Jan.18) trading at $131.99, down 0.34%.